|
|
Post by Chris-C on Dec 28, 2020 12:50:06 GMT -5
They should have spent the $105 million buying an interest in MannKind..... United Therapeutics to acquire priority review voucher for $105M It hasn’t ben that long ago when this $105M would have given them a sizeable stake in MNKD ownership... |
|
|
|
Post by buyitonsale on Dec 28, 2020 13:09:26 GMT -5
Getting royalties 4 months sooner effectively saves MNKD about 15M of cash burn .
Plus MNKD will start earning manufacturing fees sooner.
This is such unexpected and great news !
|
|
|
|
Post by kc on Dec 28, 2020 13:27:32 GMT -5
They want to beat Liquidia to market as Liquidia must have a great knockoff of the Treprostinal being a generic drug. So Martine wants to make sure they don't lose any market share especially with a blockbuster delivery device like Technosphere. LIQ861 FOR PULMONARY ARTERIAL HYPERTENSION (PAH) Our lead product candidate, LIQ861 is an inhaled dry powder formulation of treprostinil designed using our PRINT technology to enhance deep-lung delivery using a convenient, palm-sized, disposable dry powder inhaler (DPI) for the treatment of pulmonary arterial hypertension (PAH). We believe LIQ861 can overcome the limitations of current inhaled therapies and has the potential to maximize the therapeutic benefits of treprostinil in treating PAH by safely delivering higher doses into the lungs. |
|
|
|
Post by kc on Dec 28, 2020 14:15:13 GMT -5
Is this their inhaler? liquidia.com/wp-content/uploads/2016/10/Liquidia-LIQ861-PVRI-Poster-FINAL-20180124.pdf Made by Italian company? plastiape.it/en/content/1633/dry-powder-inhaler-rs01-innovationThere are plenty of pharmaceutical and biopharmaceutical research companies studying radical therapeutical innovations aiming to improve the patients’ quality of life and searching for treatments of diseases for which an efficient remedy is not yet available. Many of these research companies could not afford the very high costs and the long leadtimes necessary to design and to industrialize a new DPI. Moreover, their work is so hard and demanding on the purely chemical and pharmaceutical side of the development, that they could not have the resources to efficiently take care of the device optimization too. Only thanks to the fact that a Dry Powder Inhaler does exist, does work well, is reliable and affordable many research laboratories were able and will be able to bring their innovation to the clinical studies. Some patients might be treated in future thanks to some of the many innovative drug products developed in combination with the RS01 Monodose Dry Powder Inhaler. Plastiape regards these patients as its most important stakeholders. |
|
|
|
Post by harryx1 on Dec 28, 2020 14:30:46 GMT -5
Is this their inhaler? liquidia.com/wp-content/uploads/2016/10/Liquidia-LIQ861-PVRI-Poster-FINAL-20180124.pdf Made by Italian company? plastiape.it/en/content/1633/dry-powder-inhaler-rs01-innovationThere are plenty of pharmaceutical and biopharmaceutical research companies studying radical therapeutical innovations aiming to improve the patients’ quality of life and searching for treatments of diseases for which an efficient remedy is not yet available. Many of these research companies could not afford the very high costs and the long leadtimes necessary to design and to industrialize a new DPI. Moreover, their work is so hard and demanding on the purely chemical and pharmaceutical side of the development, that they could not have the resources to efficiently take care of the device optimization too. Only thanks to the fact that a Dry Powder Inhaler does exist, does work well, is reliable and affordable many research laboratories were able and will be able to bring their innovation to the clinical studies. Some patients might be treated in future thanks to some of the many innovative drug products developed in combination with the RS01 Monodose Dry Powder Inhaler. Plastiape regards these patients as its most important stakeholders. Yes, that is the inhaler they will be using. |
|
|
|
Post by mytakeonit on Dec 28, 2020 14:35:05 GMT -5
And this all happened before the end of the year ? It sounds like more nonsense !!!
But, that's mytakeonit
|
|
|
|
Post by kc on Dec 28, 2020 15:20:34 GMT -5
And this all happened before the end of the year ? It sounds like more nonsense !!! But, that's mytakeonit it's a race to who gets to market first. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 28, 2020 15:30:47 GMT -5
Is this their inhaler? liquidia.com/wp-content/uploads/2016/10/Liquidia-LIQ861-PVRI-Poster-FINAL-20180124.pdf Made by Italian company? plastiape.it/en/content/1633/dry-powder-inhaler-rs01-innovationThere are plenty of pharmaceutical and biopharmaceutical research companies studying radical therapeutical innovations aiming to improve the patients’ quality of life and searching for treatments of diseases for which an efficient remedy is not yet available. Many of these research companies could not afford the very high costs and the long leadtimes necessary to design and to industrialize a new DPI. Moreover, their work is so hard and demanding on the purely chemical and pharmaceutical side of the development, that they could not have the resources to efficiently take care of the device optimization too. Only thanks to the fact that a Dry Powder Inhaler does exist, does work well, is reliable and affordable many research laboratories were able and will be able to bring their innovation to the clinical studies. Some patients might be treated in future thanks to some of the many innovative drug products developed in combination with the RS01 Monodose Dry Powder Inhaler. Plastiape regards these patients as its most important stakeholders. Yes, that is the inhaler they will be using. Yes that's their inhaler. It's also being used by TFF Pharma (Thin Film Freezing) for their DPI. The powder is placed in capsules and inserted it into the Inhaler. The inhaler pierces the capsule and releases the powder. I think it sucks because of the design and there's no option for a Disposable "one time" Drug. MNKD has the Cricket. A much better design. Both companies do not have an actual product in the marketplace so there's no feedback on the inhaler. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 28, 2020 15:33:05 GMT -5
They want to beat Liquidia to market as Liquidia must have a great knockoff of the Treprostinal being a generic drug. So Martine wants to make sure they don't lose any market share especially with a blockbuster delivery device like Technosphere. LIQ861 FOR PULMONARY ARTERIAL HYPERTENSION (PAH) Our lead product candidate, LIQ861 is an inhaled dry powder formulation of treprostinil designed using our PRINT technology to enhance deep-lung delivery using a convenient, palm-sized, disposable dry powder inhaler (DPI) for the treatment of pulmonary arterial hypertension (PAH). We believe LIQ861 can overcome the limitations of current inhaled therapies and has the potential to maximize the therapeutic benefits of treprostinil in treating PAH by safely delivering higher doses into the lungs. I have a question - Could MNKD run into the same problem as LQDA with their Sumatriptan Product. Right now GSK has the rights and if MNKD doesn't get a deal with them could they screw MNKD? |
|
|
|
Post by factspls88 on Dec 28, 2020 15:37:39 GMT -5
Wondering if Mannkind has evaluated this device for possible patent infringement. I would assume that they have but who knows.
|
|
|
|
Post by mnkdfann on Dec 28, 2020 16:00:29 GMT -5
I'm just curious what other Pharma UTHR purchased this voucher from. Anyone here know? I didn't see it named in the filing, but I may well have missed it.
|
|
|
|
Post by Chris-C on Dec 28, 2020 16:20:01 GMT -5
I'm just curious what other Pharma UTHR purchased this voucher from. Anyone here know? I didn't see it named in the filing, but I may well have missed it. Sale was made by a company with ticker symbol YMAB (Y-mabs) which Is described as a company developing therapeutics for Cancer, presumably using monoclonal antibodies. |
|
|
|
Post by harryx1 on Dec 28, 2020 16:25:55 GMT -5
Yes, that is the inhaler they will be using. Yes that's their inhaler. It's also being used by TFF Pharma (Thin Film Freezing) for their DPI. The powder is placed in capsules and inserted it into the Inhaler. The inhaler pierces the capsule and releases the powder. I think it sucks because of the design and there's no option for a Disposable "one time" Drug. MNKD has the Cricket. A much better design. Both companies do not have an actual product in the marketplace so there's no feedback on the inhaler. A few other companies use the generic inhaler that's been around since the late 80's or early 90's. www.prnewswire.com/news-releases/novartis-out-licenses-three-copd-products-in-the-us-300382452.html |
|
|
|
Post by porkini on Dec 28, 2020 16:26:20 GMT -5
|
|
|
|
Post by winstonsmith on Dec 28, 2020 17:54:46 GMT -5
Yes that's their inhaler. It's also being used by TFF Pharma (Thin Film Freezing) for their DPI. The powder is placed in capsules and inserted it into the Inhaler. The inhaler pierces the capsule and releases the powder. I think it sucks because of the design and there's no option for a Disposable "one time" Drug. MNKD has the Cricket. A much better design. Both companies do not have an actual product in the marketplace so there's no feedback on the inhaler. A few other companies use the generic inhaler that's been around since the late 80's or early 90's. www.prnewswire.com/news-releases/novartis-out-licenses-three-copd-products-in-the-us-300382452.htmlSo we're saying MNKD has other similar competitors and doesn't necessarily hold any material advantage when it comes to delivering drug products via a dry powder inhaler? If so, I thought wrong and we can become irrelevant over a short period of time. Tell me it ain't so!!! |
|
